Latest Boardroom Shifts News

Tartana Minerals has lodged a cleansing prospectus to enable ASX quotation of over 129 million options linked to a $4.5 million placement, with exercise price set at 5.5 cents and expiry in April 2029.

RooLife Group (ASX: RLG) reported a 268% jump in FY2026 revenue to nearly $10 million, driven by rapid growth in its own food and beverage products, including RLG Coffee in China. Despite this, the company recorded a $3.58 million net loss, weighed down by impairment charges and R&D investments in renewable energy.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Critical Minerals Group names COO Pat Kelly as interim CEO following Scott Winter's resignation to lead BTP. The company confirms its strategy and Lindfield Vanadium Project plans remain steady during the transition.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

Tribeca Global Natural Resources Limited posted a remarkable $75.9 million profit after tax for FY26, driven by strong precious and base metals performance, and declared a fully franked final dividend of 10 cents per share.

Broken Hill Mines Limited posted a $48.8 million loss for FY2026, driven by acquisition-related costs and re-compliance expenses, despite a 56% revenue increase reflecting production growth at Rasp and Pinnacles mines.

Synlait Milk anticipates a modest improvement in underlying EBITDA for FY26 but expects a substantial net loss after tax, reflecting ongoing operational challenges and a tough first half.

Air New Zealand reported a $242 million net loss after tax for FY2026, hit by soaring fuel costs linked to the Middle East conflict and persistent engine issues. The airline unveiled a new strategy aiming for operational resilience and targeted growth amid ongoing cost pressures.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.